abstract
OBJECTIVE:
Androgen
receptor (AR), estrogen receptor α and β (ERα, ERβ), and progesterone
receptor (PR) are potential therapeutic targets in epithelial ovarian
cancer. In this study we evaluate the prognostic value of these hormone
receptors in ovarian cancer patients.
METHODS:
In
a prospective multicenter randomized controlled phase II trial
196
ovarian cancer patients were randomized to
carboplatin/docetaxel±celecoxib. Of 121 patients sufficient tumor tissue
was available for hormone receptor analysis. Tissue micro-arrays were
stained for
AR, ERα, ERβ, and PR. Cluster analysis was performed to
identify subgroups based on hormone receptor expression profile.
Receptor expression was correlated to progression-free survival (PFS)
and overall survival (OS) in uni- and multivariate analysis.
RESULTS:
AR,
ERα, ERβ, and PR were expressed in respectively 10%, 31%, 73%, and 19%.
In patients with synchronous metastasis tissue available (n=69
patients), discordant receptor expression was observed in 9-32%.
ERβ-expression was associated with poor PFS and OS (hazard ratios 1.88
and 1.92).
Clustering analysis revealed a subgroup with hormone receptor
negative disease that had a favorable PFS and OS.
CONCLUSION:
Hormone
receptors are expressed in the majority of ovarian cancer tumors and
may serve as therapeutic targets. Clustering analysis can reveal
subgroups with different outcome, which may prove valuable in selecting
patients for endocrine therapy.
0 comments :
Post a Comment
Your comments?
Note: Only a member of this blog may post a comment.